Contraflu is an R&D company developing a breakthrough product for the treatment of influenza and flu-like infections in patients with chronic diseases who cannot use existing flu medications due to safety concerns. Contraflu is a clinical stage development product protected by patents in the EU, USA, Canada and China, and patent pending in India. We are seeking an investor for pivotal clinical trial in the EU and/or a strategic partner for co-development and commercialization.